(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.

Journal Article (Journal Article;Review)

OBJECTIVE: Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of (18)F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION: FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

Full Text

Duke Authors

Cited Authors

  • Perng, P; Marcus, C; Subramaniam, RM

Published Date

  • August 2015

Published In

Volume / Issue

  • 205 / 2

Start / End Page

  • 259 - 270

PubMed ID

  • 26204273

Electronic International Standard Serial Number (EISSN)

  • 1546-3141

Digital Object Identifier (DOI)

  • 10.2214/AJR.14.13575


  • eng

Conference Location

  • United States